You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

29 Items
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Vinorelbine - Non-Small Cell Lung Cancer (NSCLC)
Jan 2018
Cancer Type: Gynecologic, Vulva     
Intent: Palliative
Jun 2019
Cancer Type: Head and Neck     
Intent: Palliative
Jun 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Adjuvant
Funding:
New Drug Funding Program
    Vinorelbine - Adjuvant Treatment of Completely Resected Stage II or IIIa Non-Small Cell Lung Cancer
Jun 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Neoadjuvant, Curative
Jun 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Adjuvant
Funding:
New Drug Funding Program
    Vinorelbine - Adjuvant Treatment of Completely Resected Stage II or IIIa Non-Small Cell Lung Cancer
May 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Vinorelbine - Non-Small Cell Lung Cancer (NSCLC)
May 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Adjuvant
Funding:
New Drug Funding Program
    Vinorelbine - Adjuvant Treatment of Completely Resected Stage II or IIIa Non-Small Cell Lung Cancer
May 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    dexamethasone
Sep 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL), Leukemia - Acute Myeloid (AML), Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade     
Intent: Curative, Palliative
May 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative
May 2019